For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Clinical observation
Thymulin primary study · PMID 2313103
Human blood specimens in an assay-development study.
Reported findings. Assay development and age-group thymulin biomarker observations; not treatment efficacy.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. A measurement study is not a treatment trial and does not show that supplementation improves immunity.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.
Two placebo-controlled rheumatoid-arthritis trials; total sample not verified from abstract.
Reported findings. Selected study arm improved global assessment in 56% versus 17% of placebo participants; four objective measures also improved.
Nonresponse. No clear accompanying immunological changes were reported.
Harms. Abstract describes minimal adverse effects; detailed events and withdrawals require original full-text verification.
Limits. A selected-arm study proportion is not a general success rate. Full-text access failed; do not import secondary withdrawal claims or infer formulation, route or schedule.
Preparation: Synthetic nonathymulin; zinc coordination and equivalence to commercial thymulin unverified. Route: Unspecified in reviewed primary abstract; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
Nonathymulin treatment of multiple sclerosis: double-blind pilot study.
40 matched patients with active multiple sclerosis and moderate disability; six-month trial and six-month follow-up.
Reported findings. No clinical benefit was detected on the reported disability, ambulation or functional outcomes.
Nonresponse. Disability, ambulation and functional scores did not differ significantly between active and placebo groups.
Harms. No significant side effects were recorded in this small trial; general safety remains unestablished.
Limits. Results apply to this preparation and population. Dose, zinc formulation, funding and conflicts are not established by the reviewed abstract.
Preparation: Synthetic serum thymic factor/nonathymulin; commercial thymulin and zinc formulation equivalence unverified. Route: Subcutaneous in the reported trial; not automatically a route for commercial thymulin.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Clinical observation
An Analysis of the Safety and Efficacy of Topical Zinc-Thymulin to treat Androgenetic Alopecia
18 adults with androgenetic alopecia,17 men/1 woman, ages35–90; uncontrolled open-label4–10-month observations; blinded image assessment;10 subjects eligible for detailed hair-growth-index analysis.
Reported findings. Intermediate hair increased in the10-subject image subset;11 longer-treated participants showed improved visual scores.
Nonresponse. Whole-group visual score did not improve significantly,p0.07; terminal-hair measures were nonsignificant.
Harms. One transient forehead redness episode reported after sun exposure, abrasion and spray; investigator attributed it to citric-acid buffer, not independently established causation.
Limits. No randomized treatment assignment or untreated comparator; image-side randomization is not clinical randomization. Three participants also used minoxidil and/or finasteride. Variable duration, selected subgroup analyses and small sample limit attribution. Reported13/20 assessor-pooled responses must not be presented as20 distinct participants or population success rate. Paper title/conclusion claims safety/efficacy more strongly than the uncontrolled whole-group null supports. This is zinc-thymulin treatment experience, distinct from nonathymulin trials or zinc correction of endogenous thymulin levels. No indexed lifecycle notice found in bounded exact-title/DOI search; comprehensive publisher lifecycle clearance not established.
Preparation: Author-synthesized pEAKSQGGSN chemically combined with zinc in buffered topical spray; LCMS peptide purity reported above95%. Only this studied zinc complex, not free peptide or an injectable outcome. Route: Topical scalp spray; no injected immune-treatment outcome.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.